REDWOOD CITY, Calif.,
Jan. 20, 2020 /PRNewswire/
-- Nevro Corp. (NYSE: NVRO), a global medical device
company that is providing innovative, evidence-based solutions for
the treatment of chronic pain, today announced that Donald A. Middlebrook has been named Vice
President, Clinical, Regulatory and Quality, reporting directly to
Chairman, CEO and President D. Keith
Grossman. Mr. Middlebrook brings to Nevro more than 30
years of senior leadership experience in regulatory affairs,
clinical affairs and quality assurance in the medical device
industry.
"We're pleased to have a leader of Don's caliber join Nevro to
advance our clinical pipeline and oversee our global regulatory and
quality initiatives," said D. Keith
Grossman, Chairman, CEO and President of Nevro. "As a
combined organization under Don's leadership, we are improving our
efficiency and continuing our commitment to maintaining the highest
levels of clinical, regulatory and quality compliance throughout
our organization."
In his most recent experience, Mr. Middlebrook served as
Regulatory and Clinical Affairs Consultant for St. Jude Medical
since its acquisition of Thoratec in late 2015, and subsequently
served in a similar role for Abbott following its acquisition of
St. Jude Medical in early 2017. At Thoratec, Mr. Middlebrook
was Vice President of Corporate Quality and Regulatory Affairs for
19 years, where he was responsible for gaining worldwide regulatory
approvals, leading numerous groundbreaking clinical trials and
overseeing the company's quality systems. Previously, he held
leadership positions in regulatory affairs and quality assurance at
Chiron Vision and Baxter International. Mr. Middlebrook has
served as past President and Chairman of the Board for the
Regulatory Affairs Professional Society (RAPS) and nominated as a
RAPS Fellow. He holds a bachelor's degree in Biology from
California State University,
Fullerton.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the Senza spinal cord stimulation
(SCS) system, an evidence-based, non-pharmacologic neuromodulation
platform for the treatment of chronic pain. HF10 therapy has
demonstrated the ability to reduce or eliminate opioids in ≥65% of
patients across six peer-reviewed clinical studies. The
Senza® System, Senza II™ System, and the
Senza® Omnia™ System are the only SCS systems that
deliver Nevro's proprietary HF10® therapy. Senza, Senza
II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of
Nevro Corp.
To learn more about Nevro, connect with us on LinkedIn, Twitter,
Facebook and Instagram.
Investor Relations:
Juliet Cunningham
Vice President, Investor Relations
+1 650-433-3247
ir@nevro.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nevro-names-donald-a-middlebrook-to-lead-clinical-regulatory-and-quality-300989427.html
SOURCE Nevro Corp.